TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from ClearPoint Neuro ( (CLPT) ) is now available.
On November 20, 2025, ClearPoint Neuro completed its acquisition of IRRAS Holdings, Inc., enhancing its commercial scale and supporting its long-term strategy in CNS drug delivery innovation. The acquisition, valued at $5.0 million in cash and 1,325,000 shares of common stock, brings the novel IRRAflow system into ClearPoint’s portfolio, expanding its presence in neurocritical care and complementing its existing technologies. This strategic move is expected to drive operational leverage and meaningful value for stakeholders by combining IRRAS’s differentiated technology with ClearPoint’s existing ecosystem.
The most recent analyst rating on (CLPT) stock is a Hold with a $18.50 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.
Spark’s Take on CLPT Stock
According to Spark, TipRanks’ AI Analyst, CLPT is a Neutral.
ClearPoint Neuro’s stock score is primarily driven by its strong strategic initiatives and revenue growth, as highlighted in the earnings call. However, challenges with profitability, negative cash flow, and bearish technical indicators weigh down the score. The lack of profitability and dividend yield further impacts the valuation negatively.
To see Spark’s full report on CLPT stock, click here.
More about ClearPoint Neuro
ClearPoint Neuro is a global device, cell, and gene therapy-enabling company that offers precise navigation to the brain and spine. The company provides both established clinical products and preclinical development services for controlled drug and device delivery. Its flagship product, the ClearPoint Neuro Navigation System, is FDA-cleared and CE-marked. ClearPoint Neuro collaborates with healthcare and research centers worldwide, providing solutions for direct central nervous system delivery of therapeutics in preclinical studies and clinical trials.
Average Trading Volume: 1,013,588
Technical Sentiment Signal: Hold
Current Market Cap: $397.6M
Find detailed analytics on CLPT stock on TipRanks’ Stock Analysis page.